These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
814 related articles for article (PubMed ID: 33017027)
41. A Novel Promoter CpG-Based Signature for Long-Term Survival Prediction of Breast Cancer Patients. Guo Y; Mao X; Qiao Z; Chen B; Jin F Front Oncol; 2020; 10():579692. PubMed ID: 33194705 [TBL] [Abstract][Full Text] [Related]
42. Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis. Mo W; Ding Y; Zhao S; Zou D; Ding X PLoS One; 2020; 15(11):e0241924. PubMed ID: 33170908 [TBL] [Abstract][Full Text] [Related]
43. Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma. Wang F; Tang C; Gao X; Xu J Ann Transl Med; 2020 Apr; 8(7):453. PubMed ID: 32395497 [TBL] [Abstract][Full Text] [Related]
44. A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer. Yang L; Li C; Qin Y; Zhang G; Zhao B; Wang Z; Huang Y; Yang Y Front Oncol; 2021; 11():686044. PubMed ID: 34422642 [TBL] [Abstract][Full Text] [Related]
45. A seven-nuclear receptor-based prognostic signature in breast cancer. Wu F; Chen W; Kang X; Jin L; Bai J; Zhang H; Zhang X Clin Transl Oncol; 2021 Jul; 23(7):1292-1303. PubMed ID: 33210236 [TBL] [Abstract][Full Text] [Related]
46. Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer. Jiang X; Xia Y; Meng H; Liu Y; Cui J; Huang H; Yin G; Shi B Front Oncol; 2021; 11():746029. PubMed ID: 34692528 [TBL] [Abstract][Full Text] [Related]
47. Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients. Zhang D; Li Y; Yang S; Wang M; Yao J; Zheng Y; Deng Y; Li N; Wei B; Wu Y; Zhai Z; Dai Z; Kang H Cancer Med; 2021 Nov; 10(22):8222-8237. PubMed ID: 34609082 [TBL] [Abstract][Full Text] [Related]
48. Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer. Wu ZZ; Wei YJ; Li T; Zheng J; Liu YF; Han M World J Clin Cases; 2024 Feb; 12(4):700-720. PubMed ID: 38322675 [TBL] [Abstract][Full Text] [Related]
49. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M Front Immunol; 2023; 14():1198826. PubMed ID: 38035071 [TBL] [Abstract][Full Text] [Related]
50. Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive predictor of risk and unfavorable prognosis in breast cancer. Bao S; Hu T; Liu J; Su J; Sun J; Ming Y; Li J; Wu N; Chen H; Zhou M J Nanobiotechnology; 2021 Jan; 19(1):22. PubMed ID: 33436002 [TBL] [Abstract][Full Text] [Related]
51. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382 [TBL] [Abstract][Full Text] [Related]
52. Identification of an optimized glycolytic-related risk signature for predicting the prognosis in breast cancer using integrated bioinformatic analysis. Jiang D; Zhang LY; Wang DH; Liu YR Medicine (Baltimore); 2023 Sep; 102(35):e34715. PubMed ID: 37656998 [TBL] [Abstract][Full Text] [Related]
53. Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. Jiang M; Wu X; Bao S; Wang X; Qu F; Liu Q; Huang X; Li W; Tang J; Yin Y Front Immunol; 2022; 13():946468. PubMed ID: 35935965 [No Abstract] [Full Text] [Related]
54. Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes. Wang F; Fang L; Fu B; Fan C Breast Cancer; 2023 May; 30(3):478-488. PubMed ID: 36856932 [TBL] [Abstract][Full Text] [Related]
55. An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network. Sun M; Wu D; Zhou K; Li H; Gong X; Wei Q; Du M; Lei P; Zha J; Zhu H; Gu X; Huang D Breast Cancer Res Treat; 2019 May; 175(1):59-75. PubMed ID: 30715658 [TBL] [Abstract][Full Text] [Related]
56. Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer. Qi A; Ju M; Liu Y; Bi J; Wei Q; He M; Wei M; Zhao L Pathol Oncol Res; 2021; 27():600727. PubMed ID: 34257557 [No Abstract] [Full Text] [Related]
57. Construction and validation of an aging-related gene signature for prognosis prediction of patients with breast cancer. Li J; Qi C; Li Q; Liu F Cancer Rep (Hoboken); 2023 Mar; 6(3):e1741. PubMed ID: 36323529 [TBL] [Abstract][Full Text] [Related]
58. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature. Shen L; Huang H; Li J; Chen W; Yao Y; Hu J; Zhou J; Huang F; Ni C Front Immunol; 2023; 14():1199465. PubMed ID: 37469520 [TBL] [Abstract][Full Text] [Related]
59. A Ribosome-Related Prognostic Signature of Breast Cancer Subtypes Based on Changes in Breast Cancer Patients' Immunological Activity. Luan T; Song D; Liu J; Wei Y; Feng R; Wang X; Gan L; Wan J; Fang H; Li H; Gong X Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984424 [No Abstract] [Full Text] [Related]
60. Identifying and Validating of an Autophagy-Related Gene Signature for the Prediction of Early Relapse in Breast Cancer. Min Y; Feng Y; Luo H; Hu D; Wei X; He D; Yin G; Fan S Front Endocrinol (Lausanne); 2022; 13():824362. PubMed ID: 35250881 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]